ALLK Allakos Inc.

69.89
-5.73  -8%
Previous Close 75.62
Open 75.69
Price To Book 6.61
Market Cap 3,401,243,956
Shares 48,665,674
Volume 406,823
Short Ratio
Av. Daily Volume 473,739
Stock charts supplied by TradingView

NewsSee all news

  1. Block & Leviton LLP Alerts Investors of Investigations into Allakos and Sterling Bancorp for Violations of Federal Securities Laws

    BOSTON, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors and whistleblowers nationwide, reminds investors of the Firm's ongoing

  2. Allakos Reports Third Quarter 2019 Financial Results

    REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases,

  3. Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting

    REDWOOD CITY, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced upcoming

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data May 7, 2019 noted a 78% median improvement in ocular symptoms
AK002
Severe Allergic Conjunctivitis
Phase 1 data released February 19, 2019.
AK002
Indolent Systemic Mastocytosis
Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.
AK002
Chronic Urticaria
Phase 2 top-line data met primary and secondary endpoints - August 5, 2019. Extension data due 1H 2020. Phase 3 trial to commence 1Q 2020.
AK002
Eosinophilic Gastritis

Latest News

  1. Block & Leviton LLP Alerts Investors of Investigations into Allakos and Sterling Bancorp for Violations of Federal Securities Laws

    BOSTON, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors and whistleblowers nationwide, reminds investors of the Firm's ongoing

  2. Allakos Reports Third Quarter 2019 Financial Results

    REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases,

  3. Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting

    REDWOOD CITY, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced upcoming